Erythema nodosum-like panniculitis during BRAF inhibitor therapy for melanoma: never forget latent tuberculosis infection.

Abstract

Dear Editor, Targeted therapies for melanoma play a pivotal role in the management of patients with advanced BRAF-mutated disease. Despite their efficacy, these treatments are associated with a spectrum of adverse events, particularly cutaneous toxicities, including photo-aggravated eruptions, increased risk of non-melanoma skin cancers, and other less frequent manifestations. Herein, we describe a clinical case and briefly review a rare and likely under-recognized adverse event: erythema nodosum (EN)-like panniculitis during BRAF inhibitor therapy. [...].